Stifel analyst Dae Gon Ha reiterated a Buy rating on Rhythm Pharmaceuticals (NASDAQ: RYTM), following report of positive Phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE